NCT03972280View on ClinicalTrials.gov

Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

July 4, 2019

Primary Completion Date

October 4, 2022

Study Completion Date

October 4, 2022

Conditions
Hidradenitis SuppurativaPalmoplantar Pustulosis
Interventions
BIOLOGICAL

Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody

Recombinant anti-G-CSF receptor monoclonal antibody is a preservative-free, sterile liquid formulation that is suitable for intravenous infusion

Trial Locations (11)

2010

Holdsworth House Medical Practice, Darlinghurst

2145

Westmead Hospital, Westmead

2400

Bispebjerg Hospital, Copenhagen

2900

Gentofte Hospital, Hellerup

3052

The Royal Melbourne Hospital, Parkville

4000

Zealand University Hospital, Roskilde

6160

Fremantle Dermatology, Fremantle

10117

Charité - Universitätsmedizin Berlin, Berlin

44791

St. Josef Hospital, Bochum

64283

Klinikum Darmstadt, Darmstadt

01307

Universitätsklinikum Carl Gustav Carus, Dresden

Sponsors

Lead Sponsor

CSL Behring
All Listed Sponsors
lead

CSL Behring

INDUSTRY